Innovative Strategies in Managing Tardive Dyskinesia
March 1, 2019
February 29, 2020
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Postgraduate Institute for Medicine and Global Medical Education.
This activity is supported by an independent educational grant from Neurocrine Biosciences.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 contact hours. Designated for 0.2 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses
All other health care professionals completing this course will be issued a statement of participation.
This activity has been designed to meet the educational needs of physicians, physician assistants, nurse practitioners, and registered nurses engaged in the care of patients with tardive dyskinesia.
Upon completion of this activity, participants should be able to:
- Discuss the prevalence and diagnostic criteria for TD in psychiatric patients.
- Identify TD using the AIMS examination.
- Formulate evidence based treatments for TD, considering both efficacy and tolerability.
Jonathan Meyer, M.D.
Clinical Professor of Psychiatry
University of California, San Diego
Joseph McEvoy, M.D.
I.W. Case Distinguished Professor of Psychiatry
Augusta University Health
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 0.2 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosures of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Jonathan Meyer, MD
- Consulting fees: Acadia Pharmaceuticals, Neurocrine, and Teva
- Fees for Non-CME/CE Services Received from Directly from a Commercial Interest or their Agents (e.g., speakers’ bureau): Acadia Pharmaceuticals, Alkermes, Allergan, Merck, Neurocrine, Otsuka America, Inc., Sunovion, and Teva
Joseph McEvoy, MD
- Consulting fees : Neurocrine, and Teva
- Fees for Non-CME/CE Services Received from Directly from a Commercial Interest or their Agents (e.g., speakers’ bureau): Teva
- Contracted Research: Neurocrine, and Teva
Planners and Managers
Prakash Masand, MD, GME Planner and Manager
- Consulting Fees: Allergan, Lundbeck, Merck, Otsuka, Pfizer, Sunovion, and Takeda
- Fees for Non-CME/CE Services Received from Directly from a Commercial Interest or their Agents (e.g., speakers’ bureau): Allergan, Lundbeck, Merck, Otsuka, Pfizer, Sunovion, and Takeda
- Contracted Research: Allergan, and Merck
The PIM planners and managers have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Instructions for Participation and Credit
There are no fees for participating and receiving credit for this activity. During the period March 1, 2019 through February 29, 2020, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form for each module completed.
To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded.
If you successfully complete the post-test (score of 75% or higher), your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you receive a score of 74% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in these activities should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.